Results 41 to 50 of about 2,385,649 (308)
Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer
Case Reports in Oncology, 2023 In patients with non-small cell lung cancer (NSCLC) harboring a fusion of the neurotrophic receptor kinase (NTRK) gene 1 or 3, treatment with tropomyosin kinase (TRK) inhibitors have shown promising results, however so far no data on efficacy of these ...
Lorenz Frehner +4 more
doaj +1 more source
Involvement of ras p2I in Neurotrophin-induced Response of Sensory, but Not Sympathetic Neurons [PDF]
, 1993 Little is known about the signal transduction mechanisms involved in the response to neurotrophins and other neurotrophic factors in neurons, beyond the activation of the tyrosine kinase activity of the neurotrophin receptors belonging to the trk family.
Barde, Y. A. +4 more
core +3 more sources
A novel inhibitor of p75-neurotrophin receptor improves functional outcomes in two models of traumatic brain injury. [PDF]
, 2016 The p75 neurotrophin receptor is important in multiple physiological actions including neuronal survival and neurite outgrowth during development, and after central nervous system injury.
Alam, Antoine +20 more
core +1 more source
Expert Review of Clinical Pharmacology, 2019 Introduction: Detecting oncogenic drivers across multiple cancers has brought about a shift toward a more targeted therapeutic approach. Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are genomic rearrangements containing the kinase domain of ...
N. Federman, R. McDermott
semanticscholar +1 more source
NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma
Frontiers in Oncology, 2020 IntroductionGlioblastoma multiforme (GBM) is the most common primary central nervous (CNS) system malignancy with a poor prognosis. The standard treatment for GBM is neurosurgical resection, followed by radiochemotherapy and adjuvant temozolomide ...
Yuekun Wang +3 more
doaj +1 more source
BMC Cancer, 2022 Background Tropomyosin receptor kinase (TRK) fusion proteins resulting from neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare primary oncogenic drivers in a wide array of tumors.
James C. H. Yang +15 more
doaj +1 more source
Frontiers in Oncology, 2023 NTRK fusions are validated oncogenic drivers of various adult and pediatric tumor types, including thyroid cancer, and serve as a therapeutic target. Recently, tropomyosin receptor kinase (TRK) inhibitors, such as entrectinib and larotrectinib, display ...
Qing-Xiang Yu +6 more
doaj +1 more source
Inducers of epithelial mesenchymal transition and cancer stem cells in malignant pleural effusions [PDF]
, 2016 The Epithelial to Mesenchymal Transition (EMT) plays a role not only in tumor metastasis but also in tumor recurrence. This process is believed to be tightly linked to the presence of Cancer Stem Cells (CSCs) however, it is still not clear which ...
Cherubini, Emanuela +5 more
core +1 more source
Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer
Pathology and Oncology Research, 2019 NTRK gene fusions affecting the tropomyosin receptor kinase (TRK) protein family have been found to be oncogenic drivers in a broad range of cancers.
D. Wong, S. Yip, P. Sorensen
semanticscholar +1 more source
Five Trk Receptors in the Zebrafish
Developmental Biology, 1995 Using a homology-based cloning strategy we have identified five members of the Trk family in the zebrafish Danio rerio. They are homologous to the three mammalian Trk receptors in their conserved intracellular kinase regions and the organization of their extracellular regions.
Martin, Stella C. +3 more
openaire +2 more sources